• Mercadante S. Cancer Pain treatment strategies in patients with cancer. Drugs. 2022;82:1357–66. This reference is of importante because is a comprehensive review of strategies for cancer pain management.

Article  PubMed  Google Scholar 

Daeninck PJ, Bruera E. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand. 1999;43:924–38.

Article  CAS  PubMed  Google Scholar 

McNicol E, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231–56.

Article  PubMed  Google Scholar 

Bruera E, Pereira J. Neuropsychiatric toxicity of opioids. In: Jensen TS, Turner JA, Wiesenfeld-Hallen Z, eds. Proceedings of the 8th World Congress on Pain, Progress in Pain Re- search and Management, vol 8. Seattle: IASP Press, 1997: 717–38.

Pereira J, Bruera E. Emerging neuropsychiatric toxicities of opioids. In: AG Lipman, ed. Journal of Pharmaceutical Care in Pain and Symptom Control – Innovations in Drug Development, Evaluation and Use. New York: The Haworth Press Inc., 1997: 5: 3–29

•• Bramati P. Bruera E Delirium in palliative care. Cancers (Basel). 2021;13:5893. This reference is of outstanding importance because clearly explains the characteristics of many conditions of neurotoxicity.

Article  PubMed  PubMed Central  Google Scholar 

Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain. 1998;74:5–9.

Article  CAS  PubMed  Google Scholar 

Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces down regulation of spinal glutamate transporters: implications in morphine intolerance and abnormal pain sensitivity. J Neurosci. 2002;22:8312–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gallagher R. Opioid-induced neurotoxicity. Can Fam Physician. 2007;53(3):426–7.

PubMed  PubMed Central  Google Scholar 

Bruera E, Pereira J. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain. 1997;69:199–201.

Article  CAS  PubMed  Google Scholar 

Adair JC, el-Nachef A, Cutler P. Fentanyl neurotoxicity. Ann Emerg Med. 1996;27:791–2.

Article  CAS  PubMed  Google Scholar 

Andersen G, Christrup L, Sjogren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain Symptom Manage. 2003;25:74–9.

Article  CAS  PubMed  Google Scholar 

Quigley C, Joel S, Patel N, Baksh A, Slevin M. Plasma concentrations of morphine, morphine- 6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med. 2003;17:185–90.

Article  PubMed  Google Scholar 

Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Care. 2005;22:291–4.

Article  PubMed  Google Scholar 

Karunatilake H, Buckley NA. Severe neurotoxicity following oral meperidine (pethidine) overdose. Clin Toxicol (Phila). 2007;45:200–1.

Article  PubMed  Google Scholar 

Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. J Pain Palliat Care Pharmacother. 2007;21:15–25.

Article  PubMed  Google Scholar 

Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces down regulation of spinal glutamate transporters: implications in morphine intolerance and abnormal pain sensitivity. J Neurosci. 2002;22:8312–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs. 2019;33:943–55.

Article  CAS  PubMed  Google Scholar 

Smith MT, Wright AWE, Williams BE, Stuart G, Cramond T. Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management. Anesth Analg. 1999;88:109–16.

Article  CAS  PubMed  Google Scholar 

Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci. 1990;47:579–85.

Article  CAS  PubMed  Google Scholar 

Lotsch J. Opioid metabolites. J Pain Symptom Manage. 2005;29:S10–24.

Article  PubMed  Google Scholar 

Mercadante S. The role of morphine glucuronides in cancer pain. Palliat Med. 1999;13:95–104.

Article  CAS  PubMed  Google Scholar 

Mercadante S. Opioid metabolism and clinical aspects. Eur J Pharmacol. 2015;769:71–8.

Article  CAS  PubMed  Google Scholar 

Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. J Palliat Med. 2004;7:545–50.

Article  PubMed  Google Scholar 

Juba KM, Wjaler RG, Daron SM. Morphine and hydromorphone-induced hyperalgesia in a hospice patient. J Palliat Med. 2013;16:809–12.

Article  PubMed  Google Scholar 

Gong QL, Hedner J, Björkman R, et al. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain. 1992;48:249–55.

Article  CAS  Google Scholar 

Penson RT, Joel SP, Clark S, et al. Limited phase I study of morphine-3-glucuronide. J Pharm Sci. 2001;90:1810–6.

Article  CAS  PubMed  Google Scholar 

Kofke WA, Garman RH, Garman R, Rose M. Opioid neurotoxicity: role of neurotransmitter systems. Neurol Res. 2000;22:733–7.

Article  CAS  PubMed  Google Scholar 

Kofke WA, Garman RH, Garman R, Stiller R, Rose ME. Opioid neurotoxicity: fentanyl dose-response effects in rats. Anesth Analg. 1996;83:1298–306.

Article  CAS  PubMed  Google Scholar 

Schneider JA. Reserpine antagonism of morphine analgesia in mice. Proc Soc Exp Biol Med. 1994;87:614–5.

Article  Google Scholar 

Kissin I, Brown PT. Reserpine-induced changes in anesthetic action of fentanyl. Anesthesiology. 1985;62:597–600.

Article  CAS  PubMed  Google Scholar 

Mercadante S, Ferrera P, Villari P, et al. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage. 2003;26:769–75.

Article  PubMed  Google Scholar 

de la Cruz M, Ransing V, Yennu S, et al. The frequency, characteristics, and outcomes among cancer patients with delirium admitted to an acute palliative care unit. Oncologist. 2015;20:1425–31.

Article  PubMed  PubMed Central  Google Scholar 

Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160:786–94.

Article  CAS  PubMed  Google Scholar 

Reddy A, Yennurajalingam S, Pulivarthi K, et al. Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist. 2013;18:2212–20.

Article  Google Scholar 

Lim SY, Cengiz P. Opioid tolerance and opioid-induced hyperalgesia: is TrkB modulation a potential pharmacological solution? Neuropharmacology. 2022;220: 109260.

Article  CAS  PubMed  Google Scholar 

MacDonald N, Der L, Allan S, et al. Opioid hyperexcitability: the application of alternate opioid therapy. Pain. 1993;53:353–5.

Article  PubMed  Google Scholar 

Lim KH, Nguyen NN, Qian Y, et al. Frequency, outcomes, and associated factors for opioid-induced neurotoxicity in patients with advanced cancer receiving opioids in inpatient palliative care. J Palliat Med. 2018;21:1698–704.

Article  PubMed  PubMed Central  Google Scholar 

Fountain A. Visual hallucinations: a prevalence study among hospice inpatients. Palliat Med. 2001;15:19–25.

Article  CAS  PubMed  Google Scholar 

De La Cruz M, Fan J, Yennu S, et al. The frequency of missed delirium in patients referred to palliative care in a comprehensive cancer center. Support Care Cancer. 2015;23:2427–33.

Article  PubMed  Google Scholar 

Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics. 2002;43:183–94.

Article  PubMed  Google Scholar 

Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570–87.

Article  CAS